Imunon Inc., based in Lawrenceville, New Jersey, is hosting an R&D Day on September 23 at 10:00 a.m. ET to discuss its lead immunotherapy candidate, IMNN-001—a DNA plasmid-based IL-12 therapy designed for advanced ovarian cancer. The event, held at Sofitel New York, will feature live webcast access and include a question-and-answer session alongside networking opportunities. Registration is open for both in-person and virtual attendance.
IMNN-001 is being evaluated in multiple clinical programs, with a particular focus on its potential as a monotherapy or combination treatment. The company’s Phase 2 OVATION 2 trial, which enrolled 112 patients with newly diagnosed advanced ovarian cancer, assessed IMNN-001 at a dose of 100 mg/m², administered intraperitoneally weekly alongside standard chemotherapy. The therapy is developed using Imunon’s proprietary TheraPlasm platform, which aims to enhance localized delivery of the IL-12 payload.
The R&D Day will feature presentations from Imunon’s leadership, including Stacy Lindborg, CEO, and Douglas Faller, Chief Medical Officer, alongside external speakers from prominent cancer research institutions. Among the invited experts are:
- Amir Jazaeri from the University of Texas MD Anderson Cancer Center, discussing minimal residual disease clearance and combination treatment strategies. - Premal Thaker from Washington University School of Medicine, who will review the Phase 3 OVATION 3 trial’s progress. - William Bradley, a clinical trial participant from the Medical College of Wisconsin, who will share insights from the OVATION 1 study.
The event underscores Imunon’s ongoing efforts to advance IL-12-based immunotherapies for ovarian cancer, a disease with limited treatment options for advanced-stage patients. The company’s clinical pipeline remains a focal point for investors and stakeholders evaluating its potential in oncology.
Imunon’s NASDAQ-listed ticker is IMNN.
